
Wockhardt is implementing a publication-driven strategy to accelerate physician adoption of its breakthrough antibiotic Zaynich in the US market. According to reports from Moneycontrol, the Mumbai-based drugmaker is preparing for the launch of Zaynich in the US and India in the coming months, backed by key scientific publications. Dr Habil Khorakiwala, chairman of the company, stated that these publications will provide the clinical community with robust evidence of Zaynich's therapeutic potential and support its adoption as a valuable treatment option, particularly for critically ill patients facing infections caused by multidrug-resistant pathogens.
The innovation push comes amid improving business performance, with Wockhardt reporting robust financial results for the second quarter. According to latest reports, Wockhardt's consolidated net sales reached ₹929 crore in Q2 FY26, marking a 25.88% year-on-year growth. The company's standalone net sales stood at ₹561 crore, up 35.84% year-on-year. Excluding pre-launch expenses related to Zaynich, EBITDA would have been ₹201 crore, demonstrating the company's strong operational performance. The company's biotech business emerged as a key growth driver, with biotech revenue surging 68% year-on-year to ₹252 crore in the quarter and 87% in the first half to ₹487 crore, driven by strong demand for insulin products in India and emerging markets.
With US Food and Drug Administration (USFDA) approval in hand, Wockhardt is now focused on commercializing Zaynich in the world's largest pharmaceutical market. As reported by Moneycontrol, Zaynich, approved in the US for complicated urinary tract infections, including pyelonephritis, is the first drug discovered and developed in India to secure USFDA approval. The company has decided to market and distribute Zaynich in the US rather than pursue an out-licensing route, recognizing that securing regulatory approval is only half the task, with commercial success depending on winning doctor confidence and ensuring patient accessibility through formulary listings.
Wockhardt is simultaneously pursuing a broader global footprint for the antibiotic beyond the US market. According to reports from Moneycontrol, the European Medicines Agency has accepted the dossier for review across multiple indications, including complicated intra-abdominal infections, hospital-acquired pneumonia, ventilator-associated pneumonia and bloodstream infections, with a decision expected in the coming months. The company has also received approval from India's Central Drugs Standard Control Organisation (CDSCO) for manufacturing and marketing the drug.
Beyond Zaynich, Wockhardt is advancing its antibiotic pipeline with several promising developments. As reported by Moneycontrol, the company recently filed a New Drug Application for Foviscu (WCK 4282), a novel antibiotic aimed at resistant Gram-negative infections, with Phase III trials showing efficacy comparable to meropenem. Another novel antibiotic, Miqnaf (nafithromycin), is expanding beyond its approved indication in community-acquired bacterial pneumonia, with a Phase III study in acute bacterial rhinosinusitis completed successfully and a supplemental filing planned in the coming quarter. Wockhardt has discovered six novel antibacterial molecules belonging to diverse chemical classes, of which three have already been launched in the market, the fourth (Zaynich) has received US FDA and CDSCO approval, and the remaining molecules are undergoing advance stage of clinical development.